About CRB Inverbio
CRB Inverbio is a venture capital firm founded in 2010. It is primarily based out of Madrid, Spain. As of Jun 2025, CRB Inverbio has invested in 17 companies. It primarily invests in Series A round in Spain based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series A round of Prosoma Overall, CRB Inverbio portfolio has seen 2 acquisitions, namely Health in Code and Oncovision. A lot of funds co-invest with CRB Inverbio, with names like Inveready sharing a substantial percentage of its portfolio. CRB Inverbio has team of 5 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A & Seed
Portfolio Acquisitions
CRB Inverbio's List of Top Investments
CRB Inverbio has a portfolio of 17 companies. Their most notable investments are in Oncovision and Nuubo.Their portfolio spans across Spain, United Kingdom and United States. They have invested in Life Sciences, HealthTech, High Tech and 5 other sectors, across stages such as Series A, Seed stages. Here is the list of top investments by CRB Inverbio:
1. Prosoma
Developer of digital therapeutic solutions for behavioral therapy. It is offering a VR-based wearable device for treating cancer. The device provides stimulation through a gamified experience to provide modules on relaxation through meditation, guided imagery, music, and breathing therapies, as well as cognitive therapies.
Key facts about Prosoma
- Founded Year: 2017
- Location: London (United Kingdom)
- Stage: Series A
- Total Funding till date: $7.72M
- Employee Count: 37 as on Sep 30, 2026
- Investors: Convergence Partners, Simpact VC and 12 Others
- Latest Funding Round: Series A, Jun 16, 2025, $*****
Atlas Molecular Pharma engages in developing drug discovery platform called CHASSYS. The technology is an integrated platform to develop new chemical entities and repurposed drugs. It is currently working on Congenital Erythropoietic Porphyria wherein the autosomal recessive deficiency in the uroporphyrinogen III synthase (UROIIIS) enzyme causes build up of porphyrins in high concentration. Additionally, the company is also working on Prion Disease: and Tyrosianemia along with other diseases.
Key facts about Atlas Molecular Pharma
Digital automated bioinformatics platform and product development company. The company offers sequencing-based diagnostic tools for cardiovascular diseases. The company has platforms like neuroHIC and cancerHIC for genetically based interpretation of neurological and oncological diseases. Their laboratory management software, NextLIMS is the tool to support and control the processes of genetic laboratories.
Key facts about Health in Code
- Founded Year: 2006
- Location: A Coruna (Spain)
- Stage: Acquired
- Employee Count: 241 as on Aug 31, 2026
- Investors: CRB Health Tech, Merieux Equity Partners and 4 Others
- Latest Funding Round: Grant (prize money), Mar 15, 2017, $*****
- Highlight: Acquired
Venter Pharma focuses on the study of solutions for digestive pathologies, with especial attention to high population prevalence disorders such as lactose intolerance or inflammatory illnesses. It developed LacTEST,a diagnostic drug based on the active substance Gaxilose. This is a noninvasive method based on oral administration for the diagnosis of lactose intolerance. It also developed a Xylose enzymatic assay to measure xylose that can be used together with LacTEST in the diagnosis of hypolactasia. It is currently working on developing LacTEST for children and received Horizon 2020 funding for the Phase I lactase development as a biological marker to monitor some gastrointestinal diseases.
Key facts about Venter Pharma
- Founded Year: 2003
- Location: Alcobendas (Spain)
- Stage: Series A
- Employee Count: 18 as on Aug 31, 2026
- Investors: EIC Fund, CRB Health Tech and 5 Others
- Latest Funding Round: Grant (prize money), Feb 28, 2015, $*****
5. Oncovision
Oncovision manufactures various medical and diagnostic devices in the space of oncology diagnostic imaging. Its product lines include Sentinella, an intra-operative Gamma Camera, and the MAMMI PET, a breast cancer diagnostic device capable of visualizing lesions of small size and quantifying tumor activity.
Key facts about Oncovision
- Founded Year: 2003
- Location: Boston (United States)
- Stage: Acquired
- Total Funding till date: $3.84M
- Employee Count: 30 as on Sep 30, 2026
- Investors: EIC Fund, Inveready and 5 Others
- Latest Funding Round: Grant (prize money), Sep 01, 2023, $*****
- Highlight: Acquired
CRB Inverbio's Year-on-Year Investment Trends
CRB Inverbio has invested in 17 companies over the last 17 years, with an average of 0 new investment annually in the last 10 years. In 2025, it made 1 investment. Its most recent first time investment was in Prosoma.CRB Inverbio's Investments by Stage
CRB Inverbio has made 7 investments in Series A stage with an average round size of $3.91M and 3 investments in Seed stage with an average round size of $3.03M.Stage of entry | No. of Investments |
|---|---|
Series A | 7 |
Seed | 3 |
Note: We have considered here, only first round of investments
CRB Inverbio's Investments by Sector
CRB Inverbio has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, AR VR - Industry Applications and Consumer. Notably, it has invested in 15 Tech companies, 12 Enterprise (B2B) companies, 9 Software companies and at least 3 companies focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 6 |
High Tech | 4 |
HealthTech | 2 |
AR VR - Industry Applications | 1 |
Consumer | 1 |
Others | 4 |
Note: We have considered here, only first round of investments
CRB Inverbio's Investments by Geography
CRB Inverbio has made most investments in Spain (8), followed by United Kingdom where it has made 2 investments.Country | No. of Investments |
|---|---|
Spain | 8 |
United Kingdom | 2 |
United States | 1 |
Note: We have considered here, only first round of investments
CRB Inverbio's recent investments
CRB Inverbio has not made any investment in 2026 so far.Here are the most recent investments by CRB Inverbio:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 16, 2025 | United Kingdom | Series A | 1521 | [+1] | |
Jan 09, 2022 | Spain | Series A | 3964 | [+3] | |
Mar 01, 2016 | United Kingdom | Series A | 5298 | - | |
Feb 24, 2015 | Spain | Series A | 5683 | ||
Jun 18, 2014 | Spain | Series A | 8731 | - |
Acquired companies in CRB Inverbio's Portfolio
2 companies from CRB Inverbio's portfolio have been acquired. The most recent acquisition was Health in Code in Dec 2019 by Alantra for $*****.Here are CRB Inverbio's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 19, 2019 | - | - | 5287 | |
Sep 07, 2016 | Sep 12, 2012 | Series A | 1625 |
Team profile of CRB Inverbio
CRB Inverbio has a team of 5 members including 4 Partners located in Spain. CRB Inverbio's team does not sit on the board of any company as of now.Here is a list of all team members in CRB Inverbio:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Madrid | - | ||
Partner | Madrid | - | - | |
Partner | - | - | - | |
Partner | Barcelona | - | - |
Co-investors of CRB Inverbio
Over the past 17 years, 23 investors have co-invested in CRB Inverbio's portfolio companies. This includes funds and angels.
- Invested before CRB Inverbio: YouNick Mint, Simpact VC and 7 others have invested in rounds before CRB Inverbio. There is 1 company where YouNick Mint has invested before CRB Inverbio and 1 company where Simpact VC has invested before CRB Inverbio.
- Top Co-investors of CRB Inverbio: 9 investors entered a company along with CRB Inverbio. These include investors like Inveready (2 companies).
- Invested after CRB Inverbio: A total of 5 investors have invested in CRB Inverbio's portfolio after their investments. Top Investors include Europa (6 companies), EIC Fund (6 companies) and Alentia (1 company).
Recent News related to CRB Inverbio
•
Atlas Molecular Pharma closes €3M round led by Inveready to advance its clinical program in rare diseasesWebcapitalriesgo•Jan 15, 2026•Spri, Atlas Molecular Pharma, CDTI, Kereon Partners and 2 others
•
CRB Inverbío participates in Prosoma's Series A round to support its digital mental health solutions in oncology.Capital-Riesgo.es•Jun 16, 2025•Verge Fund, Impact Ventures, Prosoma, CRB Inverbio
•
Crb Health Tech Receives Investor Support From Barcelona City Council For Its Third Venture Capital FundWebcapitalriesgo•Jul 18, 2024•CRB Inverbio, Barcelona
•
CRB lifts 20 million to invest in digital health and opens in BarcelonaExpansion•Apr 28, 2024•CRB Inverbio
•
Spanish Venture Capital Fund CRB Bio II Invests €2M In Aglaris Ltd. | BioSpaceBioSpace•Mar 01, 2016•Aglaris, CRB Inverbio, AglarisCell
•
El fondo de capital riesgo CRB Bio II compromete 2 millones de Euros en Aglaris Ltd. - CRB Inverbío
CRB Inverbio•AglarisCell, CRB Inverbio
